Staar Surgical stock had its Relative Strength (RS) Rating upgraded from 80 to 84 Thursday.
This unique rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against other publicly traded companies.
History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of above 80 as they launch their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
Is Staar Surgical Stock A Buy?
Staar Surgical stock reclaimed its 200-day moving average in early April. While now is not an ideal time to invest, see if the stock goes on to establish and enter a buy zone in heavy volume.
The implantable lenses for the eye maker saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -19% to 0%. Revenue rose from 6% to 19%. The company is expected to report its latest earnings and sales numbers on or around May 8.
Staar Surgical stock earns the No. 7 rank among its peers in the Medical-Products industry group. LifeMD, Boston Scientific and DexCom are among the top 5 highly rated stocks within the group.
